Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Eisner, F; Schaberl-Moser, R; Gerger, A; Samonigg, H; Pichler, M.
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Onkologie. 2013; 36(6):368-370
Doi: 10.1159/000351252
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Eisner Florian
- Pichler Martin
- Co-Autor*innen der Med Uni Graz
- Gerger Armin
- Samonigg Hellmut
- Schaberl-Moser Renate
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Thyroid cancer (TC) is the most commonly diagnosed endocrine malignancy in developed countries. Differentiated thyroid carcinoma (DTC), which includes papillary thyroid carcinoma and follicular thyroid carcinoma (FTC), composes more than 90% of all TC cases. When DTC recurs or metastasizes to distant sites despite the use of local and radiotherapeutic treatment modalities, the currently effective treatment options are limited. Case Report: A then 40-year-old female Caucasian patient was diagnosed with FTC and underwent surgery and postoperative radioactive iodine therapy. The patient developed metastatic disease, and palliative first-line treatment with the proteasome inhibitor bortezomib was initiated. After 3 months, the patient suffered progressive pulmonary metastatic disease. Treatment with the multikinase inhibitor sorafenib was started, and after 3 months of therapy, tumor restaging demonstrated partial remission. The treatment is ongoing, and the current progression-free survival is 16 months. With the exception of mild diarrhea and hand-foot syndrome, the therapy was well tolerated, and no grade 3/4 adverse toxicities occurred. Conclusion: In our single case of metastatic FTC, sorafenib showed clinically meaningful antitumor activity accompanied by good tolerability. This case report supports the use of this drug as a potential treatment option for advanced/metastatic FTC.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma, Follicular - diagnosis Adenocarcinoma, Follicular - drug therapy
- Adult -
- Boronic Acids - therapeutic use
- Female -
- Humans -
- Kidney Neoplasms - diagnosis Kidney Neoplasms - drug therapy Kidney Neoplasms - secondary
- Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - secondary
- Niacinamide - analogs & derivatives Niacinamide - therapeutic use
- Phenylurea Compounds - therapeutic use
- Pyrazines - therapeutic use
- Thyroid Neoplasms - diagnosis Thyroid Neoplasms - drug therapy
- Treatment Failure -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Follicular thyroid cancer
- Bortezomib
- Sorafenib
- Palliative treatment